Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157976
Status:
UNKNOWN
Last Update Posted:
2005-12-01
First Post:
2005-09-08
Brief Title:
Double-Masked Study of Photrex Rostaporfin Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
Sponsor:
Miravant Pharmaceuticals
Organization:
Miravant Pharmaceuticals
Study Overview
Official Title:
A Phase III Randomized Multicenter Multinational Double-Masked Placebo-Controlled Study of Photrex Rostaporfin Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD
Status:
UNKNOWN
Status Verified Date:
2005-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to confirm the efficacy and safety of rostaporfin PHOTREX photodynamic therapy PDT in the treatment of classic and occult subfoveal choroidal neovascularization CNV associated with age-related macular degeneration AMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None